Immunocore Holdings Investor Relations Material
Latest events
Q2 2025
Immunocore Holdings
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immunocore Holdings plc
Access all reports
Immunocore Holdings plc is a commercial-stage biotechnology company focused on the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune diseases. Utilizing its proprietary T cell receptor (TCR) technology, the company aims to create transformative medicines to address unmet medical needs. Among its notable products is KIMMTRAK, designed for the treatment of patients with unresectable or metastatic uveal melanoma. Immunocore is headquartered in Abingdon, the United Kingdom, and is listed on the NASDAQ stock exchange under the ticker symbol IMCR.
Key slides for Immunocore Holdings plc
Q2 2025
Immunocore Holdings plc
Q2 2025
Immunocore Holdings plc
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
IMCR
Country
🇺🇸 United States